Inflammatory Disease, Rheumatoid Arthritis, Spondyloarthritis
Conditions
Brief summary
It is a prospective follow-up. The aim is to study the maintenance of therapeutic at 10 years and 20 years of inflammatory rheumatism (rheumatoid arthritis and spondyloarthritis)
Detailed description
All subjects were followed up on a yearly basis collection with clinical data (weight, sex, age, comorbidities, treatment), biological (VS, CRP, ACPA, lipid balance, cross laps), radiology (hand and foot radiographs and ultrasonography ), BMO Measure
Interventions
OTHERobservational follow-up:clinical, radiological et biological
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* More than 18 years * Rheumatoid arthritis meeting ACR criteria Spondyloarthritis meeting ASAS criteria
Exclusion criteria
* Patient under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| therapeutic maintenance at 20 years of follow-up | 20 years | All subjects benefit from an annual follow-up including a collection of clinical data (age, sex, weight, comorbidities, swelling and painful joints), biological (CRP, ACPA, cross laps, lipids), radiological, BMO measures (Hologic), and treatments (biological and synthetic DMARDS). Each rheumatologic modification or stop of treatment is transcribed. Therapeutic maintenance definition: modification in rheumatologic treatment (number of DMARDS at 20 years) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| evolution of lipidics parameters at 20 years of follow-up | 20 years | lipidics parameters ( total, HDL, LDL cholesterol and tryglicerides) are collected each years and modifications/evolution of these parameters will be studied |
Other
| Measure | Time frame | Description |
|---|---|---|
| evolution of BMD at 20 years of follow-up | 20 years | each 2 years during visit of follow up, BMD parameters (Hologic QDR 4500A measurements performed in pasteur 2 hospital: tscore, Zscore and BMD in in g/cm2) are collected. Osteopenia was defined by a T-score between -1 and -2.5 SD and osteoporosis by a T-score below -2.5 SD, in accordance with the World Health Organization guidelines. evolution of BMD will be studied in relation with rheumatologics treatments |
Countries
France
Contacts
Primary Contactchristian H roux, PhD
Outcome results
None listed